Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma

Max S. Topp*, Tom van Meerten, Roch Houot, Monique C. Minnema, Krimo Bouabdallah, Pieternella J. Lugtenburg, Catherine Thieblemont, Martin Wermke, Kevin W. Song, Irit Avivi, John Kuruvilla, Ulrich Dührsen, Yan Zheng, Saran Vardhanabhuti, Jinghui Dong, Adrian Bot, John M. Rossi, Vicki Plaks, Marika Sherman, Jenny J. KimAnne Kerber, Marie José Kersten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
1 Downloads (Pure)


Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). To reduce axi-cel–related toxicity, several exploratory safety management cohorts were added to ZUMA-1 (NCT02348216), the pivotal phase 1/2 study of axi-cel in refractory LBCL. Cohort 4 evaluated the rates and severity of cytokine release syndrome (CRS) and neurologic events (NEs) with earlier corticosteroid and tocilizumab use. Primary endpoints were incidence and severity of CRS and NEs. Patients received 2 × 106 anti-CD19 CAR T cells/kg after conditioning chemotherapy. Forty-one patients received axi-cel. Incidences of any-grade CRS and NEs were 93% and 61%, respectively (grade ≥ 3, 2% and 17%). There was no grade 4 or 5 CRS or NE. Despite earlier dosing, the cumulative cortisone-equivalent corticosteroid dose in patients requiring corticosteroid therapy was lower than that reported in the pivotal ZUMA-1 cohorts. With a median follow-up of 14·8 months, objective and complete response rates were 73% and 51%, respectively, and 51% of treated patients were in ongoing response. Earlier and measured use of corticosteroids and/or tocilizumab has the potential to reduce the incidence of grade ≥ 3 CRS and NEs in patients with R/R LBCL receiving axi-cel.

Original languageEnglish
Pages (from-to)388-398
Number of pages11
JournalBritish Journal of Haematology
Issue number3
Early online date29 Sep 2021
Publication statusPublished - Nov 2021


Dive into the research topics of 'Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this